Skip to Main Content
Table 1

Therapy of human pancreatic carcinoma growing in the pancreas of nude mice

Treatment groupaPancreatic tumorsMetastasisBody weight (g)
IncidenceTumor volume (mm3)
MedianRangeLiverLymphMedianRange
Saline control 10/10b 574 445–770 4/10b 9/10b 22 18–30 
Gemcitabine 10/10 230c 64–445 3/10 5/10 24 17–26 
PKI 166, 7 days/wk 10/10 162d 16–274 2/10 8/10 24 21–31 
PKI 166, 7 days/wk + gemcitabine 10/10 18d 6–80 0/10 1/10 18e 15–24 
PKI 166, 3 days/wk 10/10 174c 88–607 1/10 7/10 25 21–31 
PKI 166, 3 days/wk + gemcitabine 10/10 27d 6–72 1/10 3/10 22 15–25 
Treatment groupaPancreatic tumorsMetastasisBody weight (g)
IncidenceTumor volume (mm3)
MedianRangeLiverLymphMedianRange
Saline control 10/10b 574 445–770 4/10b 9/10b 22 18–30 
Gemcitabine 10/10 230c 64–445 3/10 5/10 24 17–26 
PKI 166, 7 days/wk 10/10 162d 16–274 2/10 8/10 24 21–31 
PKI 166, 7 days/wk + gemcitabine 10/10 18d 6–80 0/10 1/10 18e 15–24 
PKI 166, 3 days/wk 10/10 174c 88–607 1/10 7/10 25 21–31 
PKI 166, 3 days/wk + gemcitabine 10/10 27d 6–72 1/10 3/10 22 15–25 
a

L3.6pl human pancreatic cancer cells (1 × 106) were injected into the pancreas of nude mice. Seven days later, groups of mice were treated with biweekly i.p. injections of gemcitabine (125 mg/kg) alone, daily or triweekly oral feedings of PKI 166 (50 mg/kg) alone, gemcitabine and PKI 166, or saline (control). All mice were killed on day 35.

b

Number of positive mice/number of mice injected.

c

P < 0.001 versus control.

d

P < 0.0001 versus control.

e

P < 0.01 versus control.

Close Modal

or Create an Account

Close Modal
Close Modal